What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer? Clinical Oncology

摘要

In this issue, Goodin et al report on the activity of docetaxel in androgen-dependent prostate cancer. This relatively small, single-institution phase II study found that docetaxel lowered prostate-specific antigen (PSA) by greater than half in 43% of patients with prostate cancer recurrence manifested by a rise in PSA after definitive local therapy. Patients maintained noncastrate levels of testosterone throughout the study, suggesting that docetaxel, a cytotoxic agent, has clinical activity against androgen-dependent prostate cancer.1 The authors suggest that this is the first published report of docetaxel activity in this specific patient population.